Table 2.
Country | Surveillance of dapsone resistance |
Surveillance of ofloxacin resistance |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Relapsea |
Newc |
All cases |
Relapsea |
Newc |
All cases |
|||||||
No. of cases | DDS-Rb | No. of cases | DDS-Rd | No. of cases | DDS-R (%) | No. of cases | OFL-R | No. of cases | OFL-R | No. of cases | OFL-R (%) | |
Benin | 0 | 0 | 85 | 4 | 85 | 4 (4.7) | 0 | 0 | 85 | 1 | 85 | 1 |
Brazil | 187 | 25 | 26 | 2 | 213 | 27 (12.7) | 154 | 3 | 23 | 0 | 177 | 3 |
Burkina Faso | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 0 |
China | 61 | 6 | 55 | 2 | 116 | 8 (6.9) | 61 | 0 | 55 | 0 | 116 | 0 |
Colombia | — | — | — | — | — | — | — | — | — | — | — | — |
Ethiopia | 1 | 0 | 27 | 0 | 28 | 0 | 1 | 0 | 27 | 0 | 28 | 0 |
Guinea | 1 | 0 | 23 | 4 | 24 | 4 (16.7) | 1 | 0 | 23 | 0 | 24 | 0 |
India | 241 | 15 | 104 | 7 | 345 | 22 (6.4) | 242 | 10 | 139 | 7 | 381 | 17 |
Indonesia | 0 | 0 | 70 | 3 | 70 | 3 (4.3) | — | — | — | — | — | |
Mali | 20 | 1 | 115 | 2 | 135 | 3 (2.2) | 20 | 0 | 115 | 0 | 135 | 0 |
Madagascar | 13 | 0 | 103 | 1 | 116 | 1 (0.9) | 13 | 0 | 103 | 0 | 116 | 0 |
Mozambique | 5 | 0 | 0 | 0 | 5 | 0 | 7 | 0 | 0 | 0 | 7 | 0 |
Myanmar | 106 | 3 | 2 | 0 | 108 | 3 (2.8) | 106 | 0 | 2 | 0 | 108 | 0 |
Nepal | 39 | 0 | 12 | 0 | 51 | 0 | 54 | 0 | 10 | 0 | 64 | 0 |
Niger | 17 | 0 | 47 | 1 | 64 | 1 (1.6) | 18 | 0 | 47 | 0 | 65 | 0 |
Philippines | 43 | 0 | 140 | 4 | 183 | 4 (2.2) | 43 | 0 | 140 | 0 | 183 | 0 |
Vietnam | 13 | 2 | 62 | 5 | 75 | 7 (9.3) | 13 | 0 | 62 | 0 | 75 | 0 |
Pakistan | 5 | 0 | 0 | 0 | 5 | 0 | 5 | 0 | 0 | 0 | 5 | 0 |
Yemen | 8 | 0 | 6 | 0 | 14 | 0 | 8 | 0 | 2 | 0 | 10 | 0 |
Totals | 762 | 52 | 877 | 35 | 1639 | 87 (5.3) | 748 | 13 | 833 | 8 | 1581 | 21 |
—, not tested.
Number of relapse leprosy cases for which result was obtained.
Number of resistant cases among relapse cases.
Number of new leprosy cases for which result was obtained.
Number of resistant cases among new cases.